PT8A的粘膜免疫佐剂活性初步研究  

A Preliminary Study on Mucosal Immune Adjuvant Activity of PT8A

作　　者：王秋娟 陈思静[1,2] 刘林 甘思杰[1,2] 马永平 

机构地区：[1]重庆医科大学,重庆400016 [2]分子医学与肿瘤研究中心,重庆400016

出　　处：《基因组学与应用生物学》2017年第10期3979-3984,共6页Genomics and Applied Biology

基　　金：病原微生物生物安全国家重点实验室开放课题(SKLPBS1523)资助

摘　　要：本研究发现位于大肠杆菌不耐热肠毒素B亚单位(heat-labile enterotxin B subunit,LTB)的8肽(octapetptide,PT8A)具有一定的佐剂活性。我们用PT8A联合人手足口病病毒的VP1(EVP1)鼻腔免疫Balb/c小鼠,通过间接ELISA法检测小鼠血清中的特异性EVP1抗体滴度,检测结果显示PT8A+EVP1组相比PBS组和EVP1组有明显佐剂活性,初步验证了PT8A的佐剂活性。对PT8A和LTB蛋白的佐剂活性进行比较研究,结果显示,PT8A的佐剂活性明显弱于LTB,有待进一步提高。通过对PT8A免疫原性进行检测分析发现,PT8A的免疫原性明显减弱,初步确定PT8A在保留佐剂活性的同时自身免疫原性明显减弱,具有进一步开发为粘膜免疫佐剂候选分子的潜力。This study found that the an octapeptide adjuvant（PT8 A） of Escherichia coli heat-labile toxin B subunit（LTB） contained some adjuvant activities. We immunized the Balb/c mice with PT8 A（EVP1）, a human hand,foot and mouth disease virus VP1（EVP1）, and detected the titer of specific EVP1 antibodies in the serum of mice by indirect ELISA. The results showed that PT8 A group had obvious adjuvant activity compared with group PBS and group EVP1, which preliminary proved the adjuvant activity of PT8 A＋EVP1. The adjuvant activities of PT8 A and LTB proteins were compared, and the results showed that the adjuvant activity of PT8 A was significantly weaker than that of LTB, which needed further improvement. The examination and analysis of immunogenicity of PT8 A indicated that the immunogenicity of the PT8 A decreased significantly. It was preliminarily determined that the immunogenicity of PT8 A was attenuated at the same time of retention of adjuvant activity and had the potential to be further developed as a candidate for mucosal immune adjuvant.

关 键 词：PT8A LTBELISA 佐剂活性 

分 类 号：R392[医药卫生—免疫学]